GlassScriptPhysician profile
Natasha Iliskovic
NPI 1497782858
$5,175.00
in general payments reported to CMS, 2019-2025
29 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $715 · 2021: $579 · 2022: $864 · 2023: $727 · 2024: $699 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $807.66 | 2020-2025 | |
| Boston Scientific Corporation | $740.55 | 2019-2024 | Watchman Access System, Watchman Flx |
| Bard Peripheral Vascular, INC. | $465.79 | 2019-2022 | |
| Cvrx, INC. | $422.91 | 2021-2025 | Barostim Neo System |
| Abbott Laboratories | $393.00 | 2020-2025 | Ensite, Diamondback Peripheral, Cardiomems |
| Heartflow, INC. | $262.07 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $244.05 | 2021-2022 | |
| Silk Road Medical, INC. | $209.34 | 2019 | |
| Amarin Pharma, INC. | $170.15 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.05 | 2020-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $163.55 | 2019-2022 | |
| Pfizer INC. | $151.73 | 2019-2022 | |
| Amgen INC. | $137.90 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.96 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $108.65 | 2025 | Assure Wcd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Canon Medical Systems USA, INC. | $98.83 | 2023 | Pet-Ct Scanner |
| Novo Nordisk INC | $71.58 | 2024 | Ozempic |
| Bolton Medical INC | $65.63 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $64.92 | 2019-2025 | Evkeeza |
| Esperion Therapeutics, INC. | $55.41 | 2021-2024 | Nexletol |
| Tactile Systems Technology INC | $49.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.99 | 2022-2023 | Verquvo, Steglujan, Steglatro |
| Biosense Webster, INC. | $34.11 | 2023 | Carto 3 |
| Resmed Corp | $25.09 | 2022 | |
| Astellas Pharma US INC | $19.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.98 | 2021 | |
| Medtronic, INC. | $18.92 | 2022 | |
| Cook Medical LLC | $14.31 | 2023 | Cook Celect |
| Becton, Dickinson and Company | $13.39 | 2024 | Rotarexs 6 F X 135 Cm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Iliskovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.